최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기기초간호자연과학회지 = Journal of Korean biological nursing science, v.12 no.1, 2010년, pp.63 - 72
유지수 (연세대학교 간호대학 임상간호과학과, 간호정책연구소, 생행동연구센터) , 안지현 (연세대학교 간호대학 임상간호과학과) , 김두리 (연세대학교 간호대학 임상간호과학과) , 추상희 (연세대학교 간호대학 임상간호과학과, 간호정책연구소, 생행동연구센터)
Purpose: The purpose of this study is to assess the effects of raloxifene in prevention of cardiovascular disease in postmenopausal women. Methods: A systematic literature review was conducted. Data sources: The existing literature from 1986 to 2009 was searched electronically using the data base of...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
선택적 에스트로젠 수용체 조절 약물은 어떠한 능력과 관련이 있는가? | 선택적 에스트로젠 수용체 조절 약물(selective estrogen receptor modulators, SERMs)이란 에스트로젠과 구조적으로 비슷하여 에스트로젠 수용체에 결합하나 조직에 따라 에스트로젠 수용체 효현제(agonist) 또는 길항제(antagonist)로 작용하는 약물을 의미한다. 이는 에스트로젠 수용체의 두가지 아형인 ERs a와 ERs b의 발현, 수용체 친화성, 수용체 전사활성능력과관련이있다. | |
선택적 에스트로젠 수용체 조절 약물이란 무엇인가? | 선택적 에스트로젠 수용체 조절 약물(selective estrogen receptor modulators, SERMs)이란 에스트로젠과 구조적으로 비슷하여 에스트로젠 수용체에 결합하나 조직에 따라 에스트로젠 수용체 효현제(agonist) 또는 길항제(antagonist)로 작용하는 약물을 의미한다. 이는 에스트로젠 수용체의 두가지 아형인 ERs a와 ERs b의 발현, 수용체 친화성, 수용체 전사활성능력과관련이있다. | |
랄록시펜이란 무엇인가? | 랄록시펜(Raloxifene hydrochloride; EvistaⓇ; Eli Lilly and Company, Indianapolis, IN)은 타목시펜(tamoxifene)과 더불어 가장 오래된 선택적 에스트로젠 수용체 조절 약물(SERMs) 중의 하나로, 폐경기 여성에서 증가하는 골다공증(랄록시펜) 또는 유방암(타목시펜)의 예방 및 치료에 사용되지만 에스트로젠 호르몬 보충 요법의 위험성인 유방암 및 자궁내막암을 증가시키지 않는 약물이다. 랄록시펜은 골격계와 심혈관계에서는 에스트로젠 효현제로 작용하여 뼈에서 뼈 흡수를 억제함으로써 골다공증을 예방 또는 치료하는데 사용되나, 임상 연구결과 총 콜레스테롤이나 LDL 콜레스테롤을 감소시키는 것으로 알려져 있다. |
Anderson, G. L., Limacher, M., Assaf, A. R., Bassford, T., Beresford, S. A., Black, H., et al. (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. The Journal of the American Medical Association, 291, 1701-1712.
Barrett-Connor, E., Ensrud, K. E., Harper, K., Mason, T. M., Sashegyi, A., Krueger, K. A., et al. (2003). Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes. Clinical Therapeutics, 25, 919-930.
Brussaard, H. E., Gevers, L. J., Frolich, M., Kluft, C., & Krans, H. M. (1997). Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia, 40, 843-849.
Chu, S. H., Lee, M. K., Kowalski, J., Beck, J., & Schwertz, D. (2008). Effect of estrogen on ovariectomy-induced obesity in rats. Journal of Korean Biological Nursing Science, 10, 80-87.
Colacurci, N., Manzella, D., Fornaro, F., Carbonella, M., & Paolisso, G. (2003). Endothelial function and menopause: Effects of raloxifene administration. The Journal of Clinical Endocrinology & Metabolism, 88, 2135-2140.
Collins, P., Mosca, L., Geiger, M. J., Grady, D., Kornitzer, M., Amewou- Atisso, M. G., et al. (2009). Effets of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for the Heart trial: Results of subgroup analyses by age and other factors. Circulation, 119, 922-930.
Dias, A. R. Jr., Melo, R. N., Gebara, O. C., D'Amico, E. A., Nussbacher, A., Halbe, H. W., et al. (2005). Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women. Climacteric, 8, 63-70.
Duvernoy, C. S., Kulkarni, P. M., Dowsett, S. A., & Keech, C. A. (2005). Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: Incidence, patient characteristics, and effect of raloxifene. Menopause, 12, 444-452.
Engin-Ustun, Y., Ustun, Y., Meydanli, M. M., & Kafkasli, A. (2006). Effects of intranasal 17beta-estradiol and raloxifene on lipid profile and fibrinogen in hypercholesterolemic postmenopausal women: A randomized, placebo-controlled clinical trial. Gynecological Endocrinology, 22, 676-679.
Ettinger, B., Black, D. M., Mitkma, B. H., Knickerbocker, R. K., Nickelsen, T., Genant, H. K., et al. (1999). Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. The Journal of the American Medical Association, 282, 637-645.
Grady, D., Herrington, D., Bittner, V., Blumenlhal, R., Davidson, M., Hlatky, M., et al. (2002). Cardiovascular disease outcomes during 6.8 years of hormones therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). The Journal of the American Medical Association, 288, 49-57.
Griffiths, K. A., Sader, M. A., Skilton, M. R., Harmer, J. A., & Celermajer, D. S. (2003). Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease. Journal of the American College of Cardiology, 42, 698-704.
Hernandez, E., Valera, R., Alonzo, E., Bajares-Lilue, M., Carlini, R., Capriles, F., et al. (2003). Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney International, 63, 2269-2274.
Hyung, H. K. & Kim, H. S. (2008). The effect of brisk walking exercise program on body composition, blood pressure, blood glucose and blood lipid for middle-aged women with obesity. Journal of Korean Biological Nursing Science, 10, 62-68.
Iwamoto, J., Sato, Y., Uzawa, M., Takeda, T., & Matsumoto, H. (2008). Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis. Yonsei Medical Journal, 49, 119-128.
Kung, A. W., Chao, H. T., Huang, K. E., Need, A. G., Taechakraichana, N., Loh, F. H., et al. (2003). Efficacy and safety of raloxifene 60 milligrams/ day in postmeno-pausal Asian women. The Journal of Clinical Endocrinology &Metabolism, 88, 3130-3136.
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., et al. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. The British Medical Journal, 339, b2700.
Ministry of Health and Welfare and Korea Institute for Health and Social Affairs. (2005). The Third Korea National Health and Nutrition Examination Survey. Unpublished Report.
Mosca, L., Grady, D., Barrett-Connor, E., Collins, P., Wenger, N., Abramson, B. L., et al. (2009). Effect of raloxifen on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke, 40, 147- 155.
Nanetti, L., Camilletti, A., Francucci, C. M., Vignini, A., Raffaelli, F., Mazzanti, L., et al. (2008). Role of raloxifene on platelet metabolism and plasma lipids. European Journal of Clinical Investigation, 38, 117-125.
Nickelsen, T., Creatsas, G., Rechberger, T., Depypere, H., Erenus, M., Quail, D., et al. (2001). Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: Results from the Euralox 1 study. Climacteric, 4, 320-331.
Oh, E. K., Choi, H., Lee, C. M., Cho, Y. K., Kim, B. R., Ko, J. K., et al. (2006). A comparion of the effects of raloxifene and estrogen therapy on lipid profile and bone mineral density in postmenopausal women. Journal of Korean Postmenopause, 12, 19-27.
Reid, I. R., Eastell, R., Fogelman, I., Adachi, J. D., Rosen, A., Netelenbos, C., et al. (2004). A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Archives of Internal Medicine, 164, 871-879.
Regitz-Zagrosek, V., Wintermantel, T. M., & Schubert, C. (2007). Estrogens and SERMs in coronary heart disease. Current Opinion in Pharmacology, 7, 130-139.
Simoncini, T., Genazzani, A. R., & Liao, J. K. (2002). Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation, 105, 1368-1373.
Song, E. K., Yeom, J. H., Shin, H. T., Kim, S. H., Shin, W. G., & Oh, J. M. (2006). Effectiveness of raloxifene on bone mineral density and serum lipid levels in post-menopausal women with low BMD after discontinuation of hormone replacement therapy. Journal of Clinical Pharmacy and Therapeutics, 31, 421-427.
Vogelvang, T. E., Mijatovic, V., Kenemans, P., Teerlink, T., & van der Mooren, M. J. (2004). HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal women. Fertility and Sterility, 82, 1540-1549.
Walsh, B. W., Kuller, L. H., Wild , R. A., Paul, S., Farmer, M., Lawrence, J. B., et al. (1998). Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. The Journal of the American Medical Association, 279, 1445-1451.
Yildiz, M. F., Kumru, S., Godekmerdan, A., & Kutlu, S. (2005). Effects of raloxifene, hormone therapy, and soy isoflavone on serum highsensitive C-reactive protein in postmenopausal women. International Journal of Gynecology &Obstetrics, 90, 128-133.
Zeng, S., Wu, Y., Zhang, Z., Yang, X., Hui, Y., Zhang, Y., et al. (2003). Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in postmenopausal women: A randomized clinical trial in Beijing. Chinese Medical Journal, 116, 1127-1133.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.